REG - Genedrive PLC - MT-RNR1 ID kit adopted for routine use in Brighton

GenedriveAnnouncement

04/12/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231204:nRSD5986Va&default-theme=true

RNS Number : 5986V  Genedrive PLC  04 December 2023

genedrive plc

("genedrive" or the "Company")

 

Royal Sussex County Hospital, Brighton adopts the Genedrive® MT-RNR1 ID Kit
for routine use

 Further expansion of hearing loss test into the NHS

 

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company,
announces the Genedrive® MT-RNR1 ID Kit is now in routine use in the Trevor
Mann Baby Unit ("TMBU") at the Royal Sussex County Hospital ("RSCH"), part of
University Hospitals Sussex NHS Foundation Trust. This site is the second NHS
Trust in the country to be using the Genedrive test for antibiotic induced
hearing loss ("AIHL").

 

Each year approximately 450 babies are admitted to the neonatal unit in
Brighton. The simple, non-invasive test will be used routinely to guide
treatment prescription within the unit from today, 4 December 2023.

 

Inspiration Healthcare and Genedrive have been working closely with the team
at the TMBU, providing training and support, to ensure the smooth
implementation of the pharmacogenetic point of care test into the neonatal
admission process. Every mother and child that comes to RSCH, will now have
access to the life-changing test, should it be required.

 

James Cheek, Chief Executive Officer of genedrive plc, said: "Both children
and parents in Sussex will have their lives and patient pathways enhanced by
having access to this test. It also brings peace of mind and support to
clinicians in very stressful circumstances to make the right decision for the
patient. On a wider scale, it's great to see how rapid Pharmacogenetics
testing is transforming healthcare in time-critical settings, and improving
patient safety."

 

For further details, please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 James Cheek: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                         +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need pharmacogenetic platform for the diagnosis of genetic variations. This
helps clinicians to quickly access key genetic information that will help them
make the right choices over the right medicine or dosage to use for an
effective treatment. Based in the UK, the Company is at the forefront of work
on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics
impacts a medicines ability to work for you. Therefore by using
pharmacogenetics, medicines can be made safer and more effective. The Company
has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a
single-use disposable cartridge which circumvents the requirement for cold
chain logistics by providing temperature stable reagent test kits for use on
their proprietary test platform. This test allows clinicians to make a
decision on antibiotic use within 26 minutes, ensuring vital care is delivered
with no negative impact on the patient pathway.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFSAFDLEDSESE